Sophia Genetics Sa · NASDAQ:SOPH
Sophia Genetics Sa — Q2 2026 Earnings Presentation
17 slides from Sophia Genetics Sa's earnings presentation, Aug 4, 2026
Slide 1: SOPHiA GENETICS Company Overview
SOPHiA GENETICS Company Overview August 2026
Slide 2: Cautionary notices
Cautionary notices This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, pro
Slide 3: Building the Intelligence Layer for Precision Medicine
Building the Intelligence Layer for Precision Medicine Actionable Insights Healthcare generates more data than most other industries. Yet decisions are still made under uncertainty. SOPHiA DDMTM is the intelligence layer AI-native that turns healthcare data into actionable Platform insights. Our AI-
Slide 4: SOPHiA DDM – the AI Platform for Precision Medicine
SOPHiA DDMTM – the AI Platform for Precision Medicine FIRST PRINCIPLES Platform interface Application menu AI Factories Data warehouse $500M+ 391,000+ Patients analyzed in 2025 invested since inception 115,000 Patients analyzed in Q2 26 4 © SOPHiA GENETICS 2026
Slide 5: How SOPHiA DDM is Used Every Day
How SOPHiA DDMTM is Used Every Day SOPHiA CUSTOMERS TYPICAL GENOMICS WORKFL OW A A A A A A A A A A A A A A A C C C C C C C C C C C C C C C T T T T T T T T T T T T T T T GGGGGGGGGGGGGGG A A A A A A A A A A A A A A A C C C C C C C C C C C C C C C T T T T T T T T T T T T T T T BETTER OUTCOMES GGGGGGGGG
Slide 6: SOPHiA DDM Connects One of the Largest Data Networks in Healthcare
SOPHiA DDMTM Connects One of the Largest Data Networks in Healthcare Network inputs • Real-time, real-word data stream from over 391,000 patients per year • Intelligence from the brightest minds in healthcare, including 15 of the top 20 global cancer centers1 Network outputs • Actionable insights to
Slide 7: Why Customers Choose SOPHiA DDM
Why Customers Choose SOPHiA DDMTM Note: The benefits described above are illustrative and may vary depending on specific use cases and customer circumstances. Results are not guaranteed and may not be representative of all customer 7 © SOPHiA GENETICS 2026 experiences. Past outcomes do not guarantee
Slide 8: Substantial Volume and Data Growth
Substantial Volume and Data Growth Analysis volume by application type from 2015 – 2025 Data processed by SOPHiA DDM TM from 2021 to 2025 Analysis volume in 000s +40% Volume growth is being driven by sophisticated new Data compute is increasing materially, driven by volume applications such as Liqui
Slide 9: Strong, Multi-Year Revenue and Volume Growth
Strong, Multi-Year Revenue and Volume Growth Revenue, 2020 – 2025 Analysis volume, 2020 – 2025 391K $77.3M 352K $65.2M 312K $62.4M 246K $47.6M 210K $40.5M 163K $28.4M 2020 2021 2022 2023 2024 2025 2020 2021 2022 2023 2024 2025 22% CAGR since 2020 One of the most widely used AI Platforms in healthcar
Slide 10: SOPHiA's Growth Algorithm
SOPHiA’s Growth Algorithm Growth lever Recent updates as of Q2 Earnings on August 4, 2026 Leveraging data, • Signed a new, multi-year agreement with AstraZeneca to launch two BioPharma network, and Ai to companion diagnostic (CDx) programs: (1) a decentralized Solid Tumor serve BioPharma CDx, and (2
Slide 11: Land and Expand Growth Engine
Land and Expand Growth Engine Land Expand Analysis volume by customer cohort, 2015 – 2025, ’000s 24 ↑ CAGR Expansion New customers signed Cohort 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 multiple in Q2 2026 2015 cohort 19K 32K 42K 49K 52K 46K 51K 54K 64K 67K 71K 14% 3.7x 2016 cohort - 1
Slide 12: 2026 Growth Drivers
2026 Growth Drivers Continue Strong Growth in Land and Expand with New Leverage the data and Ai from the U.S. Market Applications in Liquid Biopsy SOPHiA’s network to serve and Solid Tumor BioPharma • U.S. market is relatively • Signed over 100 customers to the • Signed a new, multi-year underpenetr
Slide 13: Delivering Value to Patients and Shareholders
Delivering Value to Patients and Shareholders ~$40B+ market opportunity1 Market leading 2,700+ 993 AI $500M+ technology scientific Customers across native since invested in our AI publications 75 countries founding since inception Q2 2026 highlights FY 2025 highlights Figures as of Dec 31, 2025 67 +
Slide 14: Financial Appendix
2°. SOPHIA “ee GENETICS" Financial Appendix
Slide 15: Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin
Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin 2025 2026 (Amounts in USD Thousands) Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY IFRS Revenue $17,779 $18,323 $19,462 $21,707 $77,271 $21,688 $23,310 — — — Gross Profit $12,208 $12,270 $12,907 $14,692 $52,077 $14,749 $15,061 — — — Gross Margi
Slide 16: Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth
Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth (Amounts in USD Thousands) Q2 2025 Q2 2026 Y-o-Y Growth IFRS Revenue $18,323 $23,310 27% Current Period Constant Currency Impact (1) — (454) Constant Currency Revenue $18,323 $22,856 25% Presentation of Constant Currency Reven
Slide 17: Reconciliation of IFRS Net Loss to Adjusted EBITDA
Reconciliation of IFRS Net Loss to Adjusted EBITDA (Amounts in USD Thousands) Q2 2025 Q2 2026 IFRS loss for the period ($22,414) ($22,356) Exclude the impact of: Depreciation $942 $1,080 Amortization (1) (3) $1,428 $1,827 Interest income ($419) ($231) Interest expense $559 $1,620 Fair value adjustme